甲胎蛋白阳性胃癌相关基因及治疗的研究进展  

Research Progress on Genetic Features and Clinical Treatment of Alpha-fetoprotein-producing Gastric Cancer

作　　者：刘佳 白玉贤 魏孝礼 LIU Jia;BAI Yu-xian;WEI Xiao-li(The Affiliated Cancer Hospital of Harbin Medical University, Harbin 150081 ,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院

出　　处：《中国肿瘤》2018年第6期442-447,共6页China Cancer

摘　　要：甲胎蛋白阳性胃癌（AFPGC）因拥有独特的基因学特征及临床特点,被认为是胃癌中的一种特殊类型。由于AFPGC淋巴结转移率及肝转移率均高于普通胃癌、预后差于普通胃癌的特点,引起学者们的广泛关注。VEGF、c-Met、GPC3、SALL4等被认为与肿瘤发生、发展和转移密切相关的基因,在AFPGC中均过表达。随着靶向药物的兴起,已有针对相关靶点的药物在相关领域取得了良好效果,值得关注的是,甲磺酸阿帕替尼片、苯甲磺酸索拉非尼片等靶向药物在治疗AFPGC患者中取得了令人满意的成果。现对AFPGC近年来相关基因及治疗的进展作一综述,为临床治疗AFPGC提供参考。Alpha-fetoprotein-positive gastric cancer（AFPGC） is considered as a special type of gastric cancer because of its unique genetic and clinical features;the lymph node and liver metastasis rate is higher and the prognosis is poorer than those of common gastric cancer. The VEGF,c-Met,GPC3 and SALL4 genes,which are closely related to tumor genesis,development and metastasis,are over-expressed in APGGC. The recently developed targeted drugs,such as Apatinib,Sorafenib and Ramucirumab,have achieved satisfactory results in the treatment of AFPGC. In this article the authors review the recent research progress on the genetic features and clinical treatments in AFPGC.

关 键 词：甲胎蛋白阳性胃癌 基因 治疗 预后 

分 类 号：R735.2[医药卫生—肿瘤]